Abstract: The present invention relates to a monoclonal antibody which specifically binds to an EGF2 domain of colon cancer secreted protein-2 (CCSP-2), or an antigen-binding fragment thereof. The monoclonal antibody or the antigen-binding fragment thereof of the present invention specifically binds to the EGF2 domain of CCSP-2, and thus has significantly increased affinity compared with existing peptides specifically binding to CCSP-2 and further increased specificity compared with existing antibodies to CCSP-2. Therefore, in future, accurate diagnosis can be achieved by specific detection of CCSP-2 in the protein level.

Abstract: Provided herein are engineered cells and methods for engineering cells to deliver a therapeutic agent, e.g., a small molecule, peptide or other drug, to a cell or tissue to be treated.

Abstract: The present invention relates to the novel use of a polypeptide comprising an isolated polypeptide comprising EMI domain, four fas-1 domains and RGD motif of ?ig-h3. More particularly, the invention relates to a method for the inhibition of the adhesion, migration and/or proliferation of endothelial cells, and/or for the inhibition of angiogenesis, using the isolated polypeptide comprising EMI domain, four fas-1 domains and RGD motif of ?ig-h3, or functional equivalents thereof. Furthermore, the invention provides a method for treating or preventing angiogenesis-related diseases, using the polypeptide.